Table 3.
Immunotherapy plus antiangiogenetic.
| STUDY (#=non cited in the text) |
AGENT | PHASE | SETTING | %MSS | PRIMARY ENDPOINT | RESULTS*
*In the experimental arm when applicable |
|---|---|---|---|---|---|---|
|
NCT03442569
(46) |
nivolumab + ipilimumab + panitumumab | II | Unresectable or metastatic, II and beyond | 100 | 12 weeks ORR | 35% |
|
NCT03174405
AVETUX TRIAL (47) |
avelumab + cetuximab + FOLFOX | II | Metastatic, I line | 93 | PFS rate at 12 months | NA ORR 79.5% |
|
NCT04561336
CAVE TRIAL (48) |
avelumab + cetuximab | II | Preatreted, metastatic | 92 | OS | 11.6 months |
|
NCT04513951
AVETRIC TRIAL |
avelumab + cetuximab + FOLFOXIRI | II | Unresectable, I line | NA | ORR | Ongoing |
| NCT03396926# | pembrolizumab + capecitabine + bevacizumab | II | Unresectable, metastatic, II line and beyond | 100 | ORR | 5% |
| NCT02873195# | capecitabine + bevacizumab + atezolizumab | II | Metastatic, II line and beyond | 83 | PFS | 4.4 months |
| NCT05314101# | tislelizumab + bevacizumb + trifluridine/tipiracil | II | Metastatic (liver metastasis), III and beyond | NA | PFS | Ongoing |
| NCT04194359# | sintilimab + CAPOX + bevacizumab | II/III | Metastatic, I line | NA | PFS | Ongoing |
NA, not available.